ResearcherUniversity of Naples Federico IIActive in the last 2 years
Francesca Foschini
Matched on ORCID iD 0000-0001-5389-7390; OpenAlex author ID A5019284296. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper
Papers 5
- Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarci… Co-author DOI 10.1186/s12885-024-12936-w↗
- FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. Co-author DOI 10.2217/fon-2021-1142↗
- Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study. Co-author DOI 10.3390/cancers13194939↗
- FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Co-author DOI 10.1177/1758835920947970↗
- Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Lite… Co-author DOI 10.3390/cancers11070981↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Fabiana Napolitano · 4 shared papers, 2019–2022 · strength 0.42
- Paper FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. DOI 10.2217/fon-2021-1142↗
- Paper Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A… DOI 10.3390/cancers13194939↗
- Paper FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison wi… DOI 10.1177/1758835920947970↗
- Priscilla Cascetta · 4 shared papers, 2019–2022 · strength 0.42
- Paper FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. DOI 10.2217/fon-2021-1142↗
- Paper Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A… DOI 10.3390/cancers13194939↗
- Paper FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison wi… DOI 10.1177/1758835920947970↗
- Roberto Bianco · 4 shared papers, 2019–2022 · strength 0.42
- Paper FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. DOI 10.2217/fon-2021-1142↗
- Paper Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A… DOI 10.3390/cancers13194939↗
- Paper FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison wi… DOI 10.1177/1758835920947970↗
- Alberto Servetto · 4 shared papers, 2019–2022 · strength 0.42
- Paper FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. DOI 10.2217/fon-2021-1142↗
- Paper Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A… DOI 10.3390/cancers13194939↗
- Paper FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison wi… DOI 10.1177/1758835920947970↗
- Marina Macchini · 1 shared paper, 2024 · strength 0.16
- Antonio Avallone · 1 shared paper, 2024 · strength 0.16
- Claudia Fuchs · 1 shared paper, 2024 · strength 0.16
- Alfredo Budillon · 1 shared paper, 2024 · strength 0.16
- Maria Serena Roca · 1 shared paper, 2024 · strength 0.16
- Giampaolo Tortora · 1 shared paper, 2024 · strength 0.16
- Michele Reni · 1 shared paper, 2024 · strength 0.16
- Paolo Regi · 1 shared paper, 2020 · strength 0.09
- Caterina Vivaldi · 1 shared paper, 2020 · strength 0.09
- Isabella M. Frigerio · 1 shared paper, 2020 · strength 0.09
- Giovanni Butturini · 1 shared paper, 2020 · strength 0.09
- Nicola Silvestris · 1 shared paper, 2020 · strength 0.09
- Enrico Vasile · 1 shared paper, 2020 · strength 0.09
- Alessandro Giardino · 1 shared paper, 2019 · strength 0.08
- Roberto Girelli · 1 shared paper, 2019 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.